This company listing is no longer active
Genocea Biosciences Past Earnings Performance
Past criteria checks 0/6
Key information
10.0%
Earnings growth rate
65.8%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 75.2% |
| Return on equity | -300.3% |
| Net Margin | -1,946.2% |
| Last Earnings Update | 31 Mar 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Genocea Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 22 | 2 | -37 | 15 | 44 |
| 31 Dec 21 | 2 | -33 | 15 | 40 |
| 30 Sep 21 | 2 | -35 | 15 | 37 |
| 30 Jun 21 | 0 | -36 | 15 | 35 |
| 31 Mar 21 | 1 | -43 | 15 | 33 |
| 31 Dec 20 | 1 | -44 | 14 | 34 |
| 30 Sep 20 | 1 | -38 | 14 | 33 |
| 30 Jun 20 | 1 | -41 | 13 | 32 |
| 31 Mar 20 | 0 | -36 | 12 | 30 |
| 31 Dec 19 | 0 | -39 | 12 | 27 |
| 30 Sep 19 | 0 | -29 | 12 | 26 |
| 30 Jun 19 | 0 | -30 | 13 | 26 |
| 31 Mar 19 | 0 | -27 | 14 | 24 |
| 31 Dec 18 | 0 | -28 | 14 | 25 |
| 30 Sep 18 | 0 | -39 | 14 | 58 |
| 30 Jun 18 | 0 | -48 | 14 | 52 |
| 31 Mar 18 | 0 | -59 | 13 | 46 |
| 31 Dec 17 | 0 | -57 | 13 | 39 |
| 30 Sep 17 | 0 | -62 | 15 | 0 |
| 30 Jun 17 | 0 | -58 | 15 | 0 |
| 31 Mar 17 | 0 | -54 | 15 | 0 |
| 31 Dec 16 | 0 | -50 | 15 | 0 |
| 30 Sep 16 | 0 | -44 | 15 | 0 |
| 30 Jun 16 | 1 | -41 | 15 | 0 |
| 31 Mar 16 | 1 | -40 | 15 | 0 |
| 31 Dec 15 | 1 | -42 | 14 | 0 |
| 30 Sep 15 | 1 | -44 | 13 | 0 |
Quality Earnings: GBI1 is currently unprofitable.
Growing Profit Margin: GBI1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GBI1 is unprofitable, but has reduced losses over the past 5 years at a rate of 10% per year.
Accelerating Growth: Unable to compare GBI1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GBI1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.8%).
Return on Equity
High ROE: GBI1 has a negative Return on Equity (-300.29%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/09/11 05:33 |
| End of Day Share Price | 2022/06/14 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genocea Biosciences, Inc. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ulz | Baird |
| Mara Goldstein | Cantor Fitzgerald & Co. |
| Christopher James | FBR Capital Markets & Co. |